Glythera Launches ADC Project

(c) Nicolas Loran/Getty Images
(c) Nicolas Loran/Getty Images

UK biotech Glythera has launched a project to develop next-generation antibody drug conjugates (ADCs) for difficult-to-treat tumors, backed by funding of £1 million from government agency Innovate UK.

Dave Simpson, Glythera’s CEO, said the company is poised to bring a new generation of oncology focused therapies to the clinic that could potentially treat a variety of cancers that are associated with high relapse rates with current therapy. “With Innovate UK’s support, we aim to build a portfolio of much-needed, safe treatments to improve the lives of patients living with these devastating cancers,” he said.

ADCs are an emerging class of targeted therapeutics for treating cancer. By combining the targeting power of antibodies with the capability of highly potent toxins to kill cells, ADCs can potentially kill tumor cells while also limiting damage to healthy tissues.

Glythera said ADCs that are generated by its proprietary platform PermaLink could potentially improve clinical utility through their significantly enhanced conjugation stability, giving a better therapeutic index and overall tumor response.

The project aims to develop a portfolio of PermaLink-based ADCs by combining novel high-potency toxins with a series of ADC-viable, tumor-specific antibodies, selected according to pre-defined criteria and specifically focused towards antigens that are over-expressed in cancers that are difficult to treat.

The data generated from in vitro and in vivo studies of the conjugates will be used to prioritize the most promising candidates for pre-clinical development programs. Glythera said it intends to identify its first clinical candidate for “first-in-man” studies in 2019.

Glythera has partnered with contract research organization Covance for the project.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.